As of December 31, 2025, the Company had cash, cash equivalents and short-term securities of $220.7 million compared to $72.3 million of cash, cash equivalents, restricted cash and short-term securities as of December 31, 2024. The $148.4 million increase is primarily attributable to $291.1 million in net proceeds from equity-related issuances and $9.1 million in proceeds from sale of equity holdings, partially offset by $102.7 million used in operations, $21.8 million payoff of Hercules debt facility, $20.0 million in payments relating to the Beckley Psytech investment prior to the strategic combination, and $10.0 million investment in digital assets. The Company expects its cash, cash equivalents, short-term investments and other liquid assets to fund operations into 2029.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
- AtaiBeckley says aligned with FDA on dual-trial design Phase 3 BPL-003 program
- Cathie Wood Leverages Baidu’s Post-Earnings Dip, Sells PagerDuty
- Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial
- Buy Rating on ATAI Life Sciences Driven by Promising Phase 2a EMP-01 Efficacy and Differentiated Dosing in Social Anxiety Disorder
